Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes

Blood

Volumn 96, Issue 4, 2000, Pages 1425-1432

  Laroche, Yves ^a   Heymans, Stephane ^a   Capaert, Sophie ^a   De Cock, Frans ^a   Demarsin, Eddy ^a   Collen, Désiré ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME VARIANT; EPITOPE; FIBRINOLYTIC AGENT; NEUTRALIZING ANTIBODY; RECOMBINANT STAPHYLOKINASE; STAPHYLOKINASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BLOOD CLOT LYSIS; BOLUS INJECTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; FIBRINOLYTIC THERAPY; HAMSTER; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

EID: 0034663308     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1425.h8001425_1425_1432     Document Type: Article

References (21)

1. Fibrin-selective thrombolytic therapy for acute myocardial infarction
2. The plasminogen (fibrinolytic) system
3. Staphylokinase: A potent, uniquely fibrin-selective thrombolytic agent
4. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
5. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction
6. Primary structure and gene structure of staphylokinase
7. Recombinant staphylokinase variants with altered immunoreactivity: I, construction and characterization
8. Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction
9. Recombinant staphylokinase variants with altered immunoreactivity. III. Species variability of antibody binding patterns
10. Recombinant staphylokinase variants with altered immunoreactivity: IV, identification of variants with reduced antibody induction but intact potency
11. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase
12. High yield production and purification of recombinant staphylokinase for thrombolytic therapy
13. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension
14. Improved media for growing plasmid and cosmid clones
15. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors
16. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system
17. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents
18. Prelevance and induction of circulating antibodies against recombinant staphylokinase
19. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion